Search Results - "Krumpl, Guenther"
-
1
Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients
Published in Circulation Journal (25-12-2019)“…Background:We investigated for the first time the suitability of landiolol, an ultra-short-acting β1-specific β-blocker, for the treatment of atrial…”
Get full text
Journal Article -
2
Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation
Published in Journal of molecular medicine (Berlin, Germany) (01-02-2020)“…The cell dose in umbilical cord blood units is a major determinant for the outcome of hematopoietic cell transplantation. Prostaglandin analogs and…”
Get full text
Journal Article -
3
Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)
Published in Intensive care medicine (01-10-2024)“…Purpose Excessive tachycardia in resuscitated septic shock patients can impair hemodynamics and worsen patient outcome. We investigated whether heart rate (HR)…”
Get full text
Journal Article -
4
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
Published in Cancers (05-10-2018)“…Dendritic cells (DCs) are antigen-presenting cells that are capable of priming anti-tumor immune responses, thus serving as attractive tools to generate tumor…”
Get full text
Journal Article -
5
Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group
Published in European journal of clinical pharmacology (01-04-2017)“…Purpose The aim of this prospective study was to compare in non-Asian subjects the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of…”
Get full text
Journal Article -
6
Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites
Published in Journal of cardiovascular pharmacology (01-07-2017)“…Pharmacokinetics, pharmacodynamics, safety, and tolerability of long-term administration of landiolol, a fast-acting cardioselective β-blocker, were…”
Get full text
Journal Article -
7
Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites
Published in Journal of cardiovascular pharmacology (01-03-2018)“…The pharmacokinetics, pharmacodynamics, safety, and tolerability of long-term administration of esmolol and landiolol, a new fast-acting cardioselective…”
Get full text
Journal Article -
8
Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group
Published in European journal of pharmaceutical sciences (20-09-2016)“…To date, no data have been reported on the pharmacokinetic and pharmacodynamic properties of landiolol, a fast-acting cardioselective β1-adrenergic antagonist,…”
Get full text
Journal Article -
9
Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol
Published in Curēus (Palo Alto, CA) (22-12-2020)“…Background and objective This study involved an investigation into the pharmacokinetic and pharmacodynamic behavior of esmolol in the presence of dobutamine in…”
Get full text
Journal Article -
10
Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial
Published in Current controlled trials in cardiovascular medicine (19-11-2018)“…In patients with septic shock, the presence of an elevated heart rate (HR) after fluid resuscitation marks a subgroup of patients with a particularly poor…”
Get full text
Journal Article -
11
Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials
Published in The American journal of drug and alcohol abuse (01-05-2013)“…Background: Alcoholism is a chronic and potentially fatal disease. One of the therapeutic options is pharmacotherapy with the opioid antagonist naltrexone in…”
Get full text
Journal Article -
12
Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation
Published in Clinical therapeutics (01-02-2009)“…Abstract Background: Anagrelide hydrochloride is an anti-thrombotic agent indicated for the treatment of essential thrombocythemia (ET). In various previously…”
Get full text
Journal Article